Akebia Therapeutics (AKBA) Revenue Growth (1y) (2018 - 2026)
Akebia Therapeutics (AKBA) Revenue Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.78 Bn | 87.91 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.95 Bn | 32.20 Bn | 1.97 Bn | 2.34% |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn | 2.91% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -11.85% |
| 5 | United Therapeutics | 23.01 Bn | 20.85 Bn | 648.10 Mn | -1.62% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.41 Bn | 18.61 Bn | 1.16 Bn | 7.85% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.45 Bn | 800.70 Mn | 42.25% |
| 9 | Elanco Animal Health | 12.66 Bn | 12.23 Bn | 785.00 Mn | 14.92% |
| 10 | Akebia Therapeutics | 339.15 Mn | 176.55 Mn | 41.25 Mn | -6.61% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.61% |
| Dec 31, 2025 | 23.93% |
| Sep 30, 2025 | 57.01% |
| Jun 30, 2025 | 43.13% |
| Mar 31, 2025 | 75.84% |
| Dec 31, 2024 | -17.26% |
| Sep 30, 2024 | -10.98% |
| Jun 30, 2024 | -22.58% |
| Mar 31, 2024 | -18.49% |
| Dec 31, 2023 | 0.74% |
| Sep 30, 2023 | -13.69% |
| Jun 30, 2023 | -55.39% |
| Mar 31, 2023 | 52,538.16% |
| Dec 31, 2022 | 136.68% |
| Sep 30, 2022 | -0.09% |
| Jun 30, 2022 | 138.82% |
| Mar 31, 2022 | -99.85% |
| Dec 31, 2021 | -788.27% |
| Sep 30, 2021 | 225.04% |
| Jun 30, 2021 | -41.30% |